Medivir AB, of Stockholm, said the independent data monitoring committee recommended continuation of the ongoing randomized, double-blind phase IIa study (MIV-711-201) of MIV-711 in patients with moderate knee osteoarthritis (OA), based on a review of unblinded safety data.